Azithromycin: A critical review of the first azilide antibiotic and its role in pediatric practice

Pediatric Infectious Disease Journal

Volumn 16, Issue 11, 1997, Pages 1069-1083

  Reed, Michael D ^a   Blumer, Jeffrey L ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Azilides; Azithromycin; Macrolides

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BENZATHINE PENICILLIN; CARBAMAZEPINE; CEFACLOR; CEFIXIME; CEFPROZIL; CEFTIBUTEN; CLARITHROMYCIN; CYTOCHROME P450; ERYTHROMYCIN; LINCOSAMIDE DERIVATIVE; MACROLIDE; MIDAZOLAM; MOTILIN; OROSOMUCOID; PENICILLIN V; PENICILLIN V POTASSIUM; PROCAINE PENICILLIN; PROTEIN; RIBOSOME PROTEIN; RIBOSOME RNA; ROXITHROMYCIN; SPIRAMYCIN; STREPTOGRAMIN; THEOPHYLLINE; TRANSFER RNA; TROLEANDOMYCIN; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; OTITIS MEDIA; PHARYNGITIS; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; HUMANS;

EID: 0030696644     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199711000-00013     Document Type: Review

References (115)

1. McGuire JM, Bunch RL, Anderson RC, et al. Ilotycin, a new antibiotic. Antibiot Chemother 1952;2:281-3.
2. Haight TH, Finland M. The antibacterial action of erythromycin. Proc Soc Exp Biol Med 1952;81:175-83.
3. Haight TH, Finland M. Laboratory and clinical studies of erythromycin. N Engl J Med 1952;247:227-32.
4. Washington JA, Wilson WR. Erythromycin: a microbial and clinical perspective after 30 years of clinical use. Mayo Clin Proc 1985;60:189-203
5. Kirst HA, Sides GD. New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother 1989;33:1413-8.
6. Mollering RC Jr. Introduction: revolutionary changes in the macrolide and azilide antibiotics. Am J Med 1991;91(Suppl 3A):1S-4S.
7. Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 1992;26:46-55.
8. Drew RH, Gallis HA. Azithromycin: spectrum of activity, pharmacokinetics and clinical applications. Pharmacotherapy 1992;12:161-73.
9. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992; 11:137-52.
10. Kanatani MS, Guglielmo BJ. The new macrolides azithromycin and clarithromycin. West J Med 1994;160:31-7.
11. Hashisaki GT. Update on macrolide antibiotics. Am J Otolaryngol 1995;16:153-7.
12. Schlossberg D. Azithromycin and clarithromycin. Med Clin North Am 1995;79:803-15.
13. Zuckerman JM, Kaye KM. The newer macrolides, azithromycin and clarithromycin. Infect Dis Clin North Am 1995; 9:731-45.
14. Omura S, Tsuzuki K, Sunazuka T, et al. Macrolides with gastrointestinal motor stimulating activity. J Med Chem 1987;30:1941-3.
15. Fiese EF, Steffen SH. Comparison of the acid stability of azithromycin and erythromycin A. J Antimicrob Chemother 1990;25(Suppl A):39-47.
16. Mazzei T, Mini E, Novelli A, Periti P. Chemistry and mode of action of macrolides. J Antimicrob Chemother 1993; 31(Suppl C):1-9.
17. Menninger JR. Functional consequences of binding macrolides to ribosomes. J Antimicrob Chemother 1985;16(Suppl A):23-34.
18. Neu HC. The crisis in antibiotic resistance. Science 1992;21: 1064-73.
19. Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991;35:1267-72.
20. Leclercq R, Courvalin P. Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria. Antimicrob Agents Chemother 1991;35:1273-6.
21. Bauernfeind A. In-vitro activity of dirithromycin in comparison with other new and established macrolides. J Antimicrob Chemother 1993;31(Suppl C):39-49.
22. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(Suppl A):73-82.
23. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33: 277-82.
24. Powers JL. Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections. Pediatr Infect Dis J 1996;15(Suppl):S30-7.
25. Ednie LM, Visalli MA, Jacobs MR, Appelbaum PC. Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. Antimicrob Agents Chemother 1996; 40:1950-2.
26. Barry AL, Fuchs PC, Brown SD. Relative potencies of azithromycin, clarithromycin and five other orally administered antibiotics. J Antimicrob Chemother 1995;35:552-5.
27. Ishida K, Kaku M, Irifune K, et al. In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1994;38:790-8.
28. Cantin L, Chamberland S. In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii. Antimicrob Agents Chemother 1993;37:1993-6.
29. Blais J, Garneau V, Chamberland S. Inhibition of Toxoplasma gondii protein synthesis by azithromycin. Antimicrob Agents Chemother 1993;37:1701-3.
30. Dever LL, Jorgensen JH, Barbour AG. Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. Antimicrob Agents Chemother 1993;37:1704-6.
31. Witzig RS, Franzblau SG. Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin and fusidic acid. Antimicrob Agents Chemother 1993; 37:1997-9.
32. Stevens RC, Reed MD, Shenep JL, et al. Pharmacokinetics of azithromycin following single- and multiple-dosing in children. Pharmacotherapy 1997;17:874-80.
33. Nahata MC, Koranyi KI, Luke DR, Foulds G. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Antimicrob Agents Chemother 1995;39:1875-7.
34. Nahata MC, Koranyi KI, Gadgil SD, et al. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. Antimicrob Agents Chemother 1993;37:314-6.
35. Luke DR, Foulds G, Cohen SF, Levy B. Safety, toleration and pharmacokinetics of intravenous azithromycin. Antimicrob Agents Chemother 1996;40:2577-81.
36. Luke DR, Foulds G. Disposition of oral azithromycin in humans. Clin Pharmacol Ther 1997;61:641-8.
37. Ginsburg CM. Pharmacology of erythromycin in infants and children. Pediatr Infect Dis 1986;5:124-9.
38. Foulds G, Luke DR, Teng R, Willavize SA, Freidman H, Curatolo WJ. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. J Antimicrob Chemother 1996;37(Suppl C):37-44.
39. Zithromax (azithromycin) package insert, Pfizer Laboratories, revised December, 1996.
40. Foulds G, Chan KH, Johnson JT, Shepard RM, Johnson RB. Concentrations of azithromycin in human tonsillar tissue. Eur J Clin Microbiol Infect Dis 1991;10:853-6.
41. Patel KB, Xuan D, Tessier PR, et al. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996;40: 2375-9.
42. Cazzola M, Siniscalchi C, Vinciguerra A, et al. Evaluation of lung tissue and hilar lymph node concentrations of azithromycin. Int J Clin Pharmacol Ther 1994;32:88-91.
43. Raulston JE. Pharmacokinetics of azithromycin and erythromycin in human endometrial epithelial cells and cells infected with Chlamydia trachomatis. J Antimicrob Chemother 1994;34:765-6.
44. Worm AM, Osterlind A. Azithromycin levels in cervical mucus and plasma after a single 1.0 g oral dose for chlamydial cervicitis. Genitourin Med 1995;71:244-6.
45. Cooper MA, Nye K, Andrews JM, Wise R. The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin. J Antimicrob Chemother 1990;26: 533-8.
46. Freeman CD, Nightingale CH, Nicolau DP, et al. Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid. Antimicrob Agents Chemother 1994;38:2449-51.
47. Labro MT, Benna J El, Abdelghaffar H. Modulation of human polymophonuclear neutrophil function by macrolides: preliminary data concerning dirithromycin. J Antimicrob Chemother 1993;31(Suppl C):51-64.
48. Conte JE Jr, Golden J, Duncan S, et al. Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob Agents Chemother 1996;40:1617-22.
49. Pukander J, Rautianen M. Penetration of azithromycin into middle ear effusions in acute and secretory otitis media in children. J Antimicrob Chemother 1996;37(Suppl C):53-61.
50. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991;91(Suppl 3A):5S-11S.
51. Donowitz GR. Tissue-directed antibiotics and intracellular parasites: complex interaction of phagocytes, pathogens, and drugs. Clin Infect Dis 1994;19:26-30.
52. Scaglione F, Demartini G, Dugnani S, Fraschini F. A new model examining intracellular and extracellular activity of amoxicillin, azithromycin, and clarithromycin in infected cells. Chemotherapy 1993;39:416-23.
53. de Duve C, de Barsy T, Poole B, et al. Lysosomotropic agents. Biochem Pharmacol 1974;23:2495-531.
54. Girard AE, Cimochowski CR, Faiella JA. Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localized infection. J Antimicrob Chemother 1996;37(Suppl C):9-19.
55. Dette GA, Knothe H. The binding of erythromycin in human serum. Biochem Pharmacol 1986;35:959-66.
56. Bothe R, Mattie H, van den Broek PJ. Levels of azithromycin and alpha-1 acid glycoprotein in serum in patients with community-acquired pneumonia. Antimicrob Agents Chemother 1995;39:2801-2.
57. Kelsey JJ, Moser LR, Jennings JC, Munger MA. Presence of azithromycin breast milk concentrations: a case report. Am J Obstet Gynecol 1994;170:1375-6.
58. Shepard RM, Falkner FC. Pharmacokinetics of azithromycin in rats and dogs. J Antimicrob Chemother 1990;25(Suppl A):49-60.
59. Reed MD. Clinical pharmacokinetics of amoxicillin and clavulanic acid. Pediatric Infect Dis J 1996;1(Suppl):949-54.
60. Patamasucon P, Kaojarern S, Kusmiesz H, Nelson JD. Pharmacokinetics of erythromycin ethylsuccinate and estolate in infants under 4 months of age. Antimicrob Agents Chemother 1981;19:736-9.
61. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic interactions of macrolides. Clin Pharmacokinet 1992;23: 106-31.
62. von Rosenstiel NA, Adam D. Macrolide antibacterials: drug interactions of clinical significance. Drug Safety 1995;13: 105-22.
63. Amsden GW. Macrolides versus azalides: a drug interaction update. Ann Pharmacother 1995;29:906-17.
64. Cummins LH, Kozak PP, Gilman SA. Theophylline determinations. Ann Allergy 1976;37:450-1.
65. Weinberger M, Hudgel D, Spector S, Chidsey C. Inhibition of theophylline clearance by troleandomycin. J Allergy Clin Immunol 1977;59:228-31.
66. Rieder MJ, Spino M. The theophylline-erythromycin interaction. J Asthma 1988;25:195-204.
67. Watkins PB. Drug metabolism by cytochromes P 450 in the liver and small bowel. Gastroenterol Clin North Am 1992; 21:511-26.
68. Larrey D, Funck-Brentano C, Breil P, et al. Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem Pharmacol 1983;32:1063-8.
69. Gascon MP, Dayer P. Comparative effects of macrolide antibiotics on liver monoxygenases [Abstract]. Clin Pharmacol Ther 1991;49:158.
70. Polk RE, Drug interactions with macrolide antibiotics. In: Neu HC, Young LS, Zinner SH, eds. The new macrolides, azilides and streptogramins: pharmacology and clinical applications, New York: Dekker, 1993:73-81.
71. Nahata M. Drug interactions with azithromycin and macrolides: an overview. J Antimicrob Chemother 1996; 37(Suppl C):133-42.
72. Peeters T, Matthijs G, Depoortere I, Cachet T, Hoogmartens J, Vantrappen G. Erythromycin is a motilin agonist. Am J Physiol 1989;257:G470-4.
73. Caron F, Bouaniche M, Delatour F, et al. Effects of two oral erythromycin ethylsuccinate formulations on the motility of the small intestine in human beings. Antimicrob Agents Chemother 1996;40:1796-800.
74. 125I-motilin to duodenal muscle. Biochem Biophys Res Commun 1988;150:877-82.
75. Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993;105:1886-99.
76. Wilton LV, Pearce GL, Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br J Clin Pharmacol 1996;41:277-84.
77. Kammer RB, Short LJ. Cefaclor: summary of clinical experience. Postgrad Med J 1979;55(Suppl 4):93-7.
78. Croydon P. Worldwide clinical review of Augmentin. Postgrad Med 1984;(Suppl):71-8.
79. Tally FP, Desjardins RE, McCarthy EF, Cartwright K. Safety profile of cefixime. Pediatr Infect Dis J 1987;6:676-80.
80. Hopkins SJ, Williams D. Clinical tolerability and safety of azithromycin in children. Pediatr Infect Dis J 1995; 14(Suppl):S67-71.
81. Craft JC, Siepman N. Overview of the safety profile of clarithromycin suspension in pediatric patients. Pediatr Infect Dis J 1993;12(Suppl):S142-7.
82. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991;91(Suppl 3A):40S-45S.
83. Hopkins S. Clinical safety and tolerance of azithromycin in children. J Antimicrob Chemother 1993;31(Suppl E):111-17.
84. Treadway G, Pontani D. Paediatric safety of azithromycin: worldwide experience. J Antimicrob Chemother 1996; 37(Suppl C):143-9.
85. Boguniewicz M, Leung YM. Hypersensitivity reactions to antibiotics commonly used in children. Pediatr Infect Dis J 1995;14:221-31.
86. McLinn S. Double blind and open label studies of azithromycin in management of acute otitis media in children: a review. Pediatr Infect Dis J 1995;14(Suppl):S62-6.
87. Principi N. Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis media. Eur J Clin Microbiol Infect Dis 1995;14:669-76.
88. McCarty J. A multicenter, open label trial of azithromycin for the treatment of children with acute otitis media. Pediatr Infect Dis J 1996;15(Suppl):S10-14.
89. Aronovitz G. A multicenter, open label study of azithromycin us amoxicillin/clavulanate for the management of acute otitis media in children. Pediatr Infect Dis J 1996;15(Suppl): S15-9.
90. McLinn S. A multicenter, double blind comparison of azithromycin and amoxicillin/clavulanate for the treatment of acute otitis media in children. J Pediatr Infect Dis 1996;15(Suppl):S20-3.
91. Khurana CM. A multicenter, randomized, open label comparison of azithromycin and amoxicillin/clavulanate in acute otitis media among children attending day care or school. Pediatr Infect Dis J 1996;15(Suppl):S24-9.
92. Arguedas A, Loaiza C, Herrera M, Mohs E. Comparative trial of 3-day azithromycin versus 10-day amoxycillin/clavulanate potassium in the treatment of children with acute otitis media with effusion. Int J Antimicrob Agents 1996;6:233-8.
93. Rodriguez AF. An open study to compare azithromycin with cefaclor in the treatment of children with acute otitis media. J Antimicrob Chemother 1996;37(Suppl C):63-70.
94. O'Doherty B. An open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother 1996; 37(Suppl C):71-81.
95. Muller O. An open comparative study of azithromycin and roxithromycin in the treatment of acute upper respiratory tract infections. J Antimicrob Chemother 1996;37(Suppl C):83-92.
96. Still JG. Management of pediatric patients with group A beta-hemolytic Streptococcus pharyngitis: treatment options. Pediatr Infect Dis J 1995;14(Suppl):S57-61.
97. Pacifico L, Scopetti F, Ranucci A, Pataracchia M, Savignoni F, Chiesa C. Comparative efficacy and safety of 3-day azithromycin and 10-day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. Antimicrob Agents Chemother 1996;40:1005-8.
98. Hamill G. Multicenter evaluation of azithromycin and penicillin V in the treatment of acute streptococcal pharyngitis and tonsillitis in children. J Antimicrob Chemother 1993; 31(Suppl E):89-94.
99. O'Doherty B. Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Eur J Clin Microbiol Infect Dis 1996;15: 718-24.
100. Schaad UB, Heynen G. Evaluation of the efficacy and toleration of azithromycin vs. penicillin V in the treatment of acute streptococcal pharyngitis in children: results of a multicenter, open comparative study - The Swiss Tonsillopharyngitis Study Group. Pediatr Infect Dis J 1996;15: 791-5.
101. Roord JJ, Wolf BHM, Goossens MMHT, Kimpen JLL. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin and a 10-day course of erythromycin in children with community-acquired acute lower respiratory tract infections. Antimicrob Agents Chemother 1996;40:2765-8.
102. Casiano RR. Azithromycin and amoxicillin in the treatment of maxillary sinusitis. Am J Med 1991;91(Suppl 3A):27S-30S.
103. Amin NM, Breadon G. An open-label, noncomparative study to evaluate the efficacy, safety and tolerability of azithromycin in the treatment of patients with acute sinusitis. Clin Ther 1995;17:701-7.
104. Kuzman I, Soldo I, Schonwald S, Culig J. Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: a retrospective study. Scand J Infect Dis 1995;27:503-5.
105. Rizzato G, Montemurro L, Fraioli P, et al. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur Respir J 1995;8:398-402.
106. Kushner RA, Trofa AF, Thomas RJ, et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995;21:536-41.
107. Tursi A, Cammarota G, Montalto M, Papa A, Fedeli G, Gasbarrini G. The use of azithromycin in short-term low-dose triple therapies for Helicobacter pylori infection [Letter]. Am J Gastroenterol 1996;91:817-8.
108. Al-Assi MT, Genta RM, Karttunen TJ, Cole RA, Graham DY. Azithromycin triple therapy for Helicobacter pylori infection: azithromycin, tetracycline, and bismuth. Am J Gastroenterol 1995;90:403-5.
109. Martin DH, Sargent SJ, Wendel GD Jr, McCormack WM, Spier NA, Johnson RB. Comparison of azithromycin and ceftriaxone for the treatment of chancroid. Clin Infect Dis 1995;21:409-14.
110. Erdogru T, Agacfidan A, Onel M, Badur S, Ang O, Telloglu S. The treatment of non-gonococcal urethritis with single dose oral azithromycin. J Int Med Res 1995;23:386-93.
111. Steingrimsson O, Olafsson JH, Thorarinsson H, Ryan RW, Johnson RB, Tilton RC. Single dose azithromycin treatment of gonorrhea and infections caused by C. trachomatis and U. urealyticum in men. Sex Transm Dis 1994;21:43-6.
112. Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans: a double-blind, randomized, controlled trial. Ann Intern Med 1996;124:785-91.
113. Weber K, Wilske B, Preac-Mursic V, Thurmayr R. Azithromycin versus penicillin V for the treatment of Lyme borreliosis. Infection 1993;21:367-72.
114. Khurana CM. Issues concerning antibiotic use in child care settings. Pediatr Infect Dis J 1995;14(Suppl):S34-8.
115. Demers DM, Chan DS, Bass JW. Antimicrobial drug suspensions: a blinded comparison of taste of twelve common pediatric drugs including cefixime, cefpodoxime, cefprozil and loracarbef. Pediatr Infect Dis J 1994;13:87-9.